Organization Overview
Alternative names
ozenoxacin (xepi) (2017 NDA)
Candidiasis (Phase 2)
Candidiasis, Vulvovaginal (Phase 2)
Carcinoma (Phase 3)
Carcinoma, Squamous Cell (Phase 3)
Cardiovascular Diseases (Phase 3)
Cerebral Infarction (Phase 3)
Dermatomycoses (Phase 4)
Diarrhea (Phase 3)
Fibrosis (Phase 4)
Heart Failure (Phase 4)
Hot Flashes (Phase 4)
Hypertension (Phase 4)
Impetigo (Phase 3)
Infarction (Phase 3)
Myocardial Infarction (Phase 3)
Neoplasm Metastasis (Phase 3)
Spinal Cord Injuries (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 3)
Stroke (Phase 3)
Wounds and Injuries (Phase 2)